Apolipoprotein H (apo H), also known as P2-glycoprotein I, has recently become of interest in the field of haemostasis. As apo H is elevated in diabetes mellitus and dyslipidaemia, we wished to test the hypothesis that serum apo H concentration was related to fasting plasma glucose and insulin as well as blood pressure, body mass index, hip/waist ratio and serum lipids in normal individuals.
INTRODUCTION
Apolipoprotein H (apo H) is a single-chain glycoprotein consisting of 326 amino acid residues with a molecular weight of about 47 kDa and is involved in clotting mechanisms.' It has recently gained interest in the fields of haemostasis and lipidology.
The exact functions of apo H are unclear. although there is evidence that it inhibits platelet prothrombinase activity as well as adenosine diphosphate (ADP)-induced platelet aggregation. 2 .3 In addition. Apo H has been reported to be a cofactor for the binding of certain antiphospholipid antibodies (apA) to anionic phospholipid. which can be defined as lupus Correspondence; Dr M A Crook. E-mail: martin.crook (II' gstt.sthames. nhs. uk 494 anticoagulant activity or a positive anticardiolipin immunoabsorbent assay.4. 5 Apo H has been suggested as being an activator of lipoprotein lipase. and has been postulated to be involved in lipoprotein metabolism. particularly of triglyceride-containing Iipoproteins/' ? There have also been reports that serum apo H is raised in patients with diabetes mellitus and related to insulin resistance.I?'!' In view of these earlier findings. we wished to test the hypothesis that serum apo H was related to fasting plasma insulin and glucose concentrations in normal individuals. There are also very few data looking at whether serum apo H is related to conventional cardiovascular risk factors. and in view of this we also took the opportunity to test the hypothesis that apo H serum concentrations may be related to systolic (SBP) and diastolic (DBP) blood pressure. body mass index (BMI) and waist/hip ratio. Such a study may give further insight into how apo H is implicated in lipid pathways and whether it relates to risk factors associated with insulin resistance.
MATERIALS AND METHODS
Ethical committee approval was given for the study. Eighty-one healthy young subjects (46 females and 35 males) were recruited, mostly university or graduate students aged 20·7 ± 0·75 years. None had known malignant disease, inflammatory disease, diabetes mellitus, recent surgery or cardiovascular disease at the time of study. In addition, none were on diabetic, antihypertensive, warfarin or lipid-lowering medication at the time of the research. Subjects had been fasting for at least 12-14h overnight prior to venepuncture. About 20 mL of blood were taken and samples were immediately separated from erythrocytes and frozen at -70°C prior to analysis. A serum sample was taken for apo H and a plasma sample for fasting insulin and glucose.
After 5 min rest supine arterial SBP and DBP were measured to the nearest 2 mmHg using a standard mercury sphygmomanometer. The systolic first phase and the diastolic fifth phase were used on each occasion. Subject weight and height were recorded in indoor clothing but without shoes, and the BMI calculated using the formula: weight (kgj/height (m)" Hip and waist girth were measured by the same observer, using a tape measure at the maximum circumference at the level of the greater trochanter and half the distance between the lower rib margin and the level of the anterior iliac spine, respectively.
Serum apo H was assayed by ELISA using the method of McNally et alY Briefly, antisera against apo H were obtained from Dako (Dako Ltd, Ely, Cambs, UK) and the intra-assay coefficient of variation (CV%) was less than 7%. Serum cholesterol and triglyceride were assayed by conventional enzymatic colorimetric methods on a Cobas Fara analyser with reagents supplied by Boehringer Mannheim (Lewes, Sussex, UK). Serum HDL cholesterol was similarly measured in the supernatant after precipitation of other lipoproteins with dextran/magnesium chloride reagent. Plasma glucose was assayed by the glucose oxidase method on a Cobas Fara analyser with reagents from Boehringer Mannheim (Lewes, Sussex, UK). Plasma insulin was assayed by a radioimmunoassay and had a minimal detection Apo H and cardiovascular risk factors 495 limit of I mUlL and analytical range as determined by precision profiles of 2-200 mUlL.
Radiolabelled material was supplied by Amersham International (Amersham, Bucks, UK). The intra-assay CV was less than 8% for all these assays.
Statistical analysis
The insulin resistance index (JRI) was calculated from the following equation:" IRI fasting plasma insulin concentration 22'5e -In fasting plasma glucose concentration Serum LDL cholesterol was calculated by Friedewald's equation.
Comparisons between group means were performed using Student's t-test for parametric data. Statistical significance was taken as P < 0·05. Results are shown as the mean ± standard deviation, or ranges in parentheses if data were not normally distributed. Non-parametric data (triglyceride, insulin and IRI) were normally transformed by taking logarithms (base 10). Correlations between variables were determined using Pearson's test. A multifactorial regression model was used to study independence of the variables in relation to apo H.
RESULTS
Subject details, including plasma glucose and insulin and serum apo H concentrations, are given in Table I , along with blood pressure, lipids, BMI and hip and waist measurements. In this table mean values for females and males are compared. Table 2 depicts Pearson correlation coefficients for serum apo H against the other variables. Serum apo H correlated significantly with fasting plasma glucose (r=0'24, P=0'03) and serum LDL cholesterol in the 81 individuals (r=0'30, P=0·006). In females serum apo H correlated significantly with serum cholesterol and weakly with fasting plasma insulin and IRI. In males there was a significant correlation between serum apo H and plasma HDL cholesterol, and a weak association with fasting plasma glucose.
Multifactorial regression coefficients are shown in Table 3 for serum apo H and the other variables for the 81 subjects. Only subject sex and fasting plasma glucose remained statistically significant in the model. Serum apo H concentrations would be expected to increase by 21·7 mg/L for each single rnmol/L increase in fasting plasma glucose (95% CI 2'3-41·2), P=0'029, and to increase by 17'Omg/L if the gender is male (95% CI 0,7-33'2), P= 0·041.
DISCUSSION
Not unexpectedly, we were able to show a higher systolic and diastolic blood pressure, 8MI and waist/hip ratio in the male subjects and a lower serum HDL cholesterol than in females. There was, however, an increase in serum apo H in the males compared to the female subjects. We were able to show that in univariate analysis serum apo H correlated significantly with fasting plasma glucose and serum LDL cholesterol in the combined subject groups. The former we believe to be a novel finding. There were sex differences in that serum apo H correlated significantly in univariate analysis with serum cholesterol in females and with serum HDL cholesterol concentration in males.
Cassader et al. w have shown elevated apo H in diabetic patients, and serum apo H may relate to glycaemic control in such patients. The independent relationship we found between serum apo H and fasting blood glucose in our non-diabetic individuals in the multifactorial regression model is compatible with these observations. It is possible that plasma glucose influences apo H concentrations: this merits further study, as we are not aware of this being reported before in non-diabetic individuals. We would emphasize that we were looking at healthy young normal individuals, and our findings may therefore not be directly comparable with those in older diabetic patients.
We have also shown some useful further observations that serum apo H concentrations are independent of subject blood pressure, waist/ hip ratio and BMI. The weak correlation of apo H with plasma fasting insulin and IRI in females and fasting glucose in males is interesting, but makes it less likely that apo H is importantly related to indices of insulin resistance -although these are of course only indirect markers of this condition. Nevertheless, our findings raise the possibility that there may be gender differences in the expression of apo H, although we would emphasize that association does not imply causation.
Elevated serum apo H has been found in hyperlipidaemic patients.v!' However, some of these studies have looked at older subjects or those who have abnormal lipids, and may not be directly comparable to our findings in healthy young essentially normolipidaemic individuals. We would suggest that further studies are necessary, looking at older individuals to see if serum apo H correlates differently with our various study variables with increasing subject age.
Apo H has been found to be a component of circulating plasma lipoproteins and has a high affinity for triglyceride-containing particles. Unlike other apolipoproteins, apo H does not self-associate in aqueous solution, and its secondary, tertiary and quaternary structures are different from those of most of the other apolipoproteins.!" The effect of plasma lipids upon apo H was examined by McNally et al., 12 who found that there were no significant differences between pre-and postprandial apo H concentrations. They therefore suggested that the fasting state was not an important factor in healthy subjects for apo H. None the less the subjects in our study were fasting (overnight for at least 12 h). Apo H is also not significantly related to lipoprotein(a) or apo Al and B in healthy individuals. IS Our present study was a cohort of this previous study, where we have extended our earlier observations by looking specifically at anthropometric data and plasma glucose and insulin concentrations in relation to serum apo H concentrations.
Mention should also be made of the genetic studies of apo H which have suggested the influence of apo H polymorphism upon serum lipids. I 6-20 The apo H3 allele may be related to elevated serum triglyceride concentrations." However, it is not clear what the relationship is between serum apo H concentrations and allele status. Large population studies are needed to explore the relationship between apo H genotypes and their relationship with serum lipid fractions and other cardiovascular risk factors.
In conclusion, we were able to show significant associations between serum apo H concentrations and various serum lipid fractions and also fasting glucose. There were gender differences in the expression of these relationships, but no independent correlation between serum apo H concentrations and subject blood pressure, BMI or waist/hip ratio. The involvement of apo H in diabetes mellitus merits further research, as does how and why it relates to serum lipids.
